Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Management attributed top-line growth to the expansion of its ADHD business, notably Jornay PM’s 41% year-over-year revenue increase and broader prescriber reach. CEO Vikram Karnani stressed that the integration of recently acquired Azstarys was completed ahead of the crucial back-to-school season, reinforcing the company’s strategy to diversif

Jornay PM revenue surged 41% as Collegium integrated Azstarys and expanded its sales force.

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.

Moby summary of Collegium Pharmaceutical, Inc.'s Q2 2026 earnings call

Strong ADHD growth offsets pain portfolio pressure, with total revenues up 6% and adjusted EBITDA rising 8% year-over-year.

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise. President and Chief Executive Officer Vikram Karnani said th

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q1, starting with Collegium Pharmaceutical (NASDAQ:COLL).

Collegium Pharmaceutical Stock Update After Recent Trading Moves Collegium Pharmaceutical (COLL) has moved within a relatively tight range recently, with the stock down 0.5% over the last session but up in the past week and month. For investors tracking pain management specialists, Collegium Pharmaceutical’s roughly $1.2b market value, last close of $36.08, and 1-year total return of 15.6% set the stage for assessing whether current pricing aligns with its fundamentals. See our latest...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 11.9% over the past six months while the S&P 500 was up 8.7%.